The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention
dc.contributor.author | Braunwald, Eugene | en_US |
dc.contributor.author | Angiolillo, Dominick | en_US |
dc.contributor.author | Bates, Eric R. | en_US |
dc.contributor.author | Berger, Peter B. | en_US |
dc.contributor.author | Bhatt, Deepak | en_US |
dc.contributor.author | Cannon, Christopher P. | en_US |
dc.contributor.author | Furman, Mark I. | en_US |
dc.contributor.author | Gurba, Paul E. | en_US |
dc.contributor.author | Michelson, Alan D. | en_US |
dc.contributor.author | Peterson, Eric | en_US |
dc.contributor.author | Wiviott, Stephen | en_US |
dc.date.accessioned | 2008-05-12T13:36:13Z | |
dc.date.available | 2009-03-04T14:20:46Z | en_US |
dc.date.issued | 2008-03 | en_US |
dc.identifier.citation | Braunwald, Eugene; Angiolillo, Dominick; Bates, Eric; Berger, Peter B.; Bhatt, Deepak; Cannon, Christopher P.; Furman, Mark I.; Gurbel, Paul; Michelson, Alan D.; Peterson, Eric; Wiviott, Stephen (2008). "The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention." Clinical Cardiology 31(S1): I-17-I-20. <http://hdl.handle.net/2027.42/58557> | en_US |
dc.identifier.issn | 0160-9289 | en_US |
dc.identifier.issn | 1932-8737 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/58557 | |
dc.description.abstract | Platelets play a central role in the atherosclerotic inflammatory response, thrombotic vascular occlusion, microembolization, vasoconstriction, and plaque progression. Persistent platelet activation poses a serious problem among patients with acute coronary syndromes (ACS) and those who have undergone percutaneous coronary intervention (PCI), placing them at risk for ischemic events and subacute stent thrombosis. Patients undergoing PCI are at risk for further ischemic events because of procedure-related platelet activation as well as the inherent persistent platelet hyperreactivity and enhanced thrombin generation associated with ACS. Persistent platelet activation following an acute coronary event and/or PCI supports incorporating antiplatelet strategies into the standard medical management of such patients. In this clinical setting, antiplatelet therapies are capable of improving outcomes. Aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors, the 3 major pharmacologic approaches to persistent platelet activation, target various levels of the hemostatic pathways and thrombus formation. Copyright © 2008 Wiley Periodicals, Inc. | en_US |
dc.format.extent | 105995 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Medicine and Healthcare | en_US |
dc.subject.other | Cardiovascular Disease | en_US |
dc.title | The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialities | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; | en_US |
dc.contributor.affiliationother | TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; ; TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, University of Florida College of Medicine, Jacksonville, Florida; | en_US |
dc.contributor.affiliationother | Geisinger Center for Health Research, Danville, Pennsylvania; | en_US |
dc.contributor.affiliationother | Department of Cardiovascular Medicine, Cardiovascular Coordinating Center, Cleveland Clinic, Cleveland, Ohio; | en_US |
dc.contributor.affiliationother | TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; | en_US |
dc.contributor.affiliationother | Cardiovascular Medicine, South Shore Hospital, South Weymouth, Massachusetts; | en_US |
dc.contributor.affiliationother | Department of Medicine, Sinai Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland; | en_US |
dc.contributor.affiliationother | Center for Platelet Function Studies, Pediatrics, Medicine, and Pathology, University of Massachusetts Medical School, Worcester, Massachusetts; | en_US |
dc.contributor.affiliationother | Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA | en_US |
dc.contributor.affiliationother | TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts; | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/58557/1/20363_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/clc.20363 | en_US |
dc.identifier.source | Clinical Cardiology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.